{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:03:55Z","timestamp":1773907435819,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T07:21:38Z","timestamp":1631344898000},"page":"6174-6181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers"],"prefix":"10.1016","volume":"39","author":[{"given":"Tomoki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.001_b0005","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1016\/j.vaccine.2017.11.003","article-title":"Equination (inoculation of horsepox): An early alternative to vaccination (inoculation of cowpox) and the potential role of horsepox virus in the origin of the smallpox vaccine","volume":"35","author":"Esparza","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.09.001_b0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0025727300040825","article-title":"Jenner's smallpox vaccine. The riddle of vaccinia virus and its origin","volume":"26","author":"Wilkinson","year":"1982","journal-title":"Med Hist"},{"key":"10.1016\/j.vaccine.2021.09.001_b0015","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMc1707600","article-title":"An Early American Smallpox Vaccine Based on Horsepox","volume":"377","author":"Schrick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0020","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/340517","article-title":"Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination","volume":"185","author":"Ennis","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.amjmed.2008.08.019","article-title":"Immunity from smallpox vaccine persists for decades: a longitudinal study","volume":"121","author":"Taub","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/375824","article-title":"Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0040","doi-asserted-by":"crossref","unstructured":"Henderson DA, Klepac P. Lessons from the eradication of smallpox: an interview with D. A. Henderson. Philos Trans R Soc Lond B Biol Sci. 2013;368:20130113.","DOI":"10.1098\/rstb.2013.0113"},{"key":"10.1016\/j.vaccine.2021.09.001_b0045","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/JVI.02797-14","article-title":"Evolution of and evolutionary relationships between extant vaccinia virus strains","volume":"89","author":"Qin","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0050","series-title":"Vaccines for Biodefense and Emerging and Neglected Diseases","first-page":"685","article-title":"Chapter 37 - Smallpox","author":"Kennedy","year":"2009"},{"key":"10.1016\/j.vaccine.2021.09.001_b0055","unstructured":"Arita I. Can we stop smallpox vaccination? The cessation of vaccination will not only save thousands of patients who would otherwise have suffered from complications but will also save the world community some $1,000 million a year. World Health;1980 May p27-29;. 1980."},{"key":"10.1016\/j.vaccine.2021.09.001_b0060","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1073\/pnas.80.17.5364","article-title":"Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin","volume":"80","author":"Panicali","year":"1983","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.09.001_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2021.09.001_b0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(05)70209-9","article-title":"Smallpox vaccines: from first to second to third generation","volume":"365","author":"Poland","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.001_b0075","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, World Health O. Smallpox and its eradication \/ F. Fenner ... [et al.]. Geneva: World Health Organization; 1988."},{"key":"10.1016\/j.vaccine.2021.09.001_b0080","doi-asserted-by":"crossref","unstructured":"Metzger W, Mordmueller BG. Vaccines for preventing smallpox. Cochrane Database Syst Rev. 2007:CD004913.","DOI":"10.1002\/14651858.CD004913.pub2"},{"key":"10.1016\/j.vaccine.2021.09.001_b0085","first-page":"279","article-title":"Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells","volume":"54","author":"Hekker","year":"1976","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2021.09.001_b0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2021.09.001_b0095","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2013a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Infect Dis."},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2021.09.001_b0100","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1086\/524749","article-title":"Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board","volume":"46","author":"Neff","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jviromet.2010.04.012","article-title":"Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome","volume":"168","author":"Cottingham","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2021.09.001_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192725","article-title":"Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8","volume":"13","author":"Yoshikawa","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0130","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1073\/pnas.192420599","article-title":"Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells","volume":"99","author":"Domi","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.09.001_b0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2021.09.001_b0140","first-page":"1149","article-title":"Hochstein-Mintzel V","volume":"113","author":"Stickl","year":"1971","journal-title":"Munch Med Wochenschr"},{"key":"10.1016\/j.vaccine.2021.09.001_b0145","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"Holzner A","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.vaccine.2021.09.001_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2021.09.001_b0155","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2021.09.001_b0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.09.001_b0170","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.09.001_b0175","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.09.001_b0180","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0185","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.09.001_b0190","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(94)90215-1","article-title":"Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines","volume":"12","author":"Sugimoto","year":"1994","journal-title":"Vaccine."},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2021.09.001_b0195","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1099\/0022-1317-68-10-2705","article-title":"Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination","volume":"68","author":"Takahashi-Nishimaki","year":"1987","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0200","series-title":"Vaccinia Virus as Vectors for Vaccine Antigens","first-page":"87","article-title":"Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain","author":"Hashizume","year":"1985"},{"key":"10.1016\/j.vaccine.2021.09.001_b0205","first-page":"269","article-title":"Vaccination research groups research report: Ministry of Health and Welfare special research: postvaccination side effects and research regarding treatment of complications","volume":"3","author":"Yamaguchi","year":"1975","journal-title":"Rinsho To Uirusu"},{"key":"10.1016\/j.vaccine.2021.09.001_b0210","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.2009.289","article-title":"Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8","volume":"301","author":"Saito","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.09.001_b0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01314664","article-title":"Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys","volume":"53","author":"Morita","year":"1977","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/192381a0","article-title":"A new mutant of dermovaccinia virus","volume":"192","author":"Tagaya","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.09.001_b0225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/viro.2002.1622","article-title":"Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector","volume":"302","author":"Ishii","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.09.001_b0230","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0235","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/vaccines2040755","article-title":"Vaccinia Virus LC16m8 as a Vaccine Vector for Clinical Applications","volume":"2","author":"Kidokoro","year":"2014","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.vaccine.2021.09.001_b0240","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.09.001_b0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.09.001_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviromet.2007.03.012","article-title":"The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L\u2013K2L genes","volume":"144","author":"Zhu","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2021.09.001_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004180","article-title":"A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination","volume":"4","author":"Huang","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0260","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.vaccine.2007.11.045","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination","volume":"26","author":"Vijaysri","year":"2008","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.09.001_b0265","doi-asserted-by":"crossref","first-page":"20005","DOI":"10.1038\/s41598-019-56550-4","article-title":"Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector","volume":"9","author":"Giel-Moloney","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.09.001_b0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/civ792","article-title":"Viral Hemorrhagic Fever Diagnostics","volume":"62","author":"Racsa","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7861\/clinmedicine.15-1-61","article-title":"Viral haemorrhagic fever","volume":"15","author":"Fhogartaigh","year":"2015","journal-title":"Clin Med (Lond)."},{"key":"10.1016\/j.vaccine.2021.09.001_b0280","series-title":"Encyclopedia of Microbiology (Third Edition)","first-page":"339","author":"Hemorrhagic","year":"2009"},{"key":"10.1016\/j.vaccine.2021.09.001_b0285","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever","volume":"2","author":"Clegg","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.001_b0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0168-1702(88)90033-0","article-title":"Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection","volume":"9","author":"Auperin","year":"1988","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2021.09.001_b0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.86.1.317","article-title":"Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene","volume":"86","author":"Fisher-Hoch","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.09.001_b0300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/rmv.329","article-title":"Towards a human Lassa fever vaccine","volume":"11","author":"Fisher-Hoch","year":"2001","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0305","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.09.001_b0310","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model","volume":"9","author":"Julander","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0315","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever\u2013challenges for the development and use of vaccines","volume":"357","author":"Monath","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0320","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2010.10-0001","article-title":"Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States","volume":"82","author":"Monath","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.09.001_b0325","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14760584.2019.1698952","article-title":"Ebola vaccine trials: progress in vaccine safety and immunogenicity","volume":"18","author":"Matz","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2021.09.001_b0330","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.09.001_b0335","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0340","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmv.21721","article-title":"The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines","volume":"82","author":"Pilankatta","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0355","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation","volume":"93","author":"Pasin","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0360","doi-asserted-by":"crossref","unstructured":"Kitonsa J, Ggayi AB, Anywaine Z, Kisaakye E, Nsangi L, Basajja V, et al. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda. Glob Health Action. 2020;13:1829829.","DOI":"10.1080\/16549716.2020.1829829"},{"key":"10.1016\/j.vaccine.2021.09.001_b0365","doi-asserted-by":"crossref","unstructured":"Shukarev G, Callendret B, Luhn K, Douoguih M, consortium E. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Human vaccines & immunotherapeutics. 2017;13:266-70.","DOI":"10.1080\/21645515.2017.1264755"},{"key":"10.1016\/j.vaccine.2021.09.001_b0370","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0375","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.001_b0380","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0385","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00363-18","article-title":"Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins","volume":"92","author":"Lazaro-Frias","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.09.001_b0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007564","article-title":"Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine","volume":"15","author":"Rahim","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.09.001_b0395","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","article-title":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","volume":"37","author":"Kennedy","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.09.001_b0400","article-title":"A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection","volume":"7","author":"Lopez-Gil","year":"2013","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2021.09.001_b0405","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2014.05.020","article-title":"Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs","volume":"108","author":"Busquets","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2021.09.001_b0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13567-018-0516-z","article-title":"Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination","volume":"49","author":"Lorenzo","year":"2018","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2021.09.001_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses","volume":"11","author":"Dowall","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0420","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","article-title":"A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease","volume":"12","author":"Dowall","year":"2016","journal-title":"Human vaccines & immunotherapeutics."},{"key":"10.1016\/j.vaccine.2021.09.001_b0425","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jiac.2018.07.009","article-title":"Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy","volume":"24","author":"Saijo","year":"2018","journal-title":"J Infect Chemother."},{"key":"10.1016\/j.vaccine.2021.09.001_b0430","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.39.17-00661","article-title":"Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers","volume":"22","author":"Hewson","year":"2017","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2021.09.001_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008859","article-title":"A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome","volume":"17","author":"Yoshikawa","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.09.001_b0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111736","article-title":"Age is a critical risk factor for severe fever with thrombocytopenia syndrome","volume":"9","author":"Ding","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165207","article-title":"Epidemiological and Clinical Features of Severe Fever with Thrombocytopenia Syndrome in Japan, 2013\u20132014","volume":"11","author":"Kato","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.09.001_b0450","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.vaccine.2020.01.055","article-title":"Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial","volume":"38","author":"Samy","year":"2020","journal-title":"Vaccine."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:39Z","timestamp":1759403019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21011695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":90,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21011695"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}